Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimustine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy

Junya Miyahara¹, Naoki Takezako¹, Miyuki Wagatsuma², Kiyoe Midorikawa², Ichiro Fukuda³, Satoshi Noto¹, Ikuo Saito⁴, Kazuaki Yamada², Akiyoshi Miwa⁵, Naohiro Sekiguchi¹*

¹Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan; ²Division of Pathology, National Hospital Organization Disaster Medical Center, Japan; ³Division of Radiology, National Hospital Organization Disaster Medical Center, Japan; ⁴Division of Pathology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan; ⁵Hematology Division, National Center for Global Health and Medicine, Japan.

Email: *nao26@aol.com

Received January 11th, 2013; revised January 25th, 2013; accepted February 4th, 2013

ABSTRACT

The prognosis of CD20-positive (CD20+) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) recurrence is still poor. A standard treatment for CD20+ DLBCL with CNS recurrence in elderly patients has not been established mainly due to adverse effects. We previously reported the efficacy and safety of MIND-E (ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide) therapy for elderly CD20+ DLBCL patients with CNS recurrence. Here, we report the use of R-MIND-E therapy (rituximab, ranimustine, ifosfamide, procarbazine, dexamethasone and etoposide) in an elderly CD20+ DLBCL patient with CNS recurrence. The patient achieved a complete response according to Revised Response Criteria for Malignant Lymphoma, and treatment -related toxicity was tolerable. R-MIND-E therapy may be a feasible and useful treatment option for elderly CD20+ DLBCL patients with CNS recurrence.

Keywords: Diffuse Large B-Cell Lymphoma; Central Nervous System Recurrence; Rituximab; MIND-E

1. Introduction

The prognosis of CD20-positive (CD20+) diffuse large B-cell lymphoma (DLBCL) has been improved by combining CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen [1]. However, the prognosis of CD20+ DLBCL with central nervous system (CNS) recurrence is still poor [2]. Whole brain irradiation or high dose chemotherapy including methotrexate (MTX) and cytarabine is useful for younger patients; however, these therapies are not appropriate for elderly CD20+ DLBCL patients with CNS recurrence because of treatment-related toxicities including leukoencephalopathy. We previously reported the efficacy and safety of MIND-E therapy (ranimustine (MCNU), ifosfamide (IFO), procarbazine (PCZ), dexamethasone (DEX), and etoposide (ETP)) (Table 1(a)). On the other hand, we did not use rituximab in the study [3]. Recently, regarding primary CNS lymphoma (PCNSL), intravenous rituximab in addition to combined chemotherapy has been accepted as the standard treatment strategy [4-7]. Furthermore, CNS recurrence of systemic DLBCL is usually premonitory symptom of systemic recurrence, therefore, administration of rituximab in the salvage therapy may be considered as prevention for systemic reoccurrence. Here, we report a case of an elderly CD20+ DLBCL patient with CNS recurrence treated with R-MIND-E therapy.

2. Case Report

A 69-year-old male was admitted to our hospital in March 2010 because of right hemilateral sensory disturbance, short-term memory disturbance, alexia, and agraphia. He had been diagnosed with CD20+ primary testicular DLBCL in 2005, and underwent orchidectomy. 6 cycles of CHOP therapy, irradiation, and intrathecal injection for CNS prophylaxis. He achieved a complete response (CR). T2 weighted magnetic resonance imaging
Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimustine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy

Table 1. (a) Regimen of MIND-E therapy; (b) Regimen of R-MIND-E therapy.

(a)

<table>
<thead>
<tr>
<th>Dose</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranimustine</td>
<td>50 mg/m² div</td>
<td>○</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>500 mg/m² div</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Procarbazine</td>
<td>80 mg/m² po</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Etoposide</td>
<td>100 mg/m² div</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>40 mg/body div</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
</tbody>
</table>

(b)

<table>
<thead>
<tr>
<th>Dose</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6 or 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranimustine</td>
<td>50 mg/m² div</td>
<td>○</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>500 mg/m² div</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td></td>
</tr>
<tr>
<td>Procarbazine</td>
<td>100 mg/m² po</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>80 mg/m² div</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>40 mg/body div</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>375 mg/m² div</td>
<td>○</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

po: per os; div: drip infusion of vein.

(MRI) revealed a high-intensity mass in the left temporal lobe to parietal lobe (Figure 1(a)). Laboratory results were as follows: WBC 5900/μL, Hb 12.8 mg/dL, and LDH 209 IU/L. The total cell count in the cerebrospinal fluid (CSF) was 63/μL. May-Giemsa staining of the CSF smear showed the diffuse infiltration of atypical large lymphocytes (Figure 2). Therefore, he was diagnosed with CNS recurrence of DLBCL.

He was evaluated to be a poor candidate for whole brain irradiation and high-dose chemotherapy because of his age and poor performance status. Therefore, he was treated with MIND-E therapy. After 4 cycles of MIND-E therapy, MRI (Figure 1(b)) and [18F]-fluorodeoxyglucose positron emission tomography (PET) scans showed no evidence of a tumor, and all detectable clinical evidence of disease and disease-related symptoms disappeared; thus, he achieved CR according to Revised Response Criteria for Malignant Lymphoma [8]. Six months later, MRI revealed second CNS recurrence (Figure 1(c)). At that time, he was treated with 3 cycles of R-MIND-E therapy (Table 1(b)). One cycle of R-MIND-E therapy consisted of the intravenous administration of 50 mg/m² MCNU on day 1, intravenous administration of 500 mg/m² IFO on days 1 - 5, oral administration of 100 mg/m² PCZ on days 1 - 5, intravenous administration of 80 mg/m² ETP on days 1 - 5, intravenous administration of 40 mg/body DEX on days 1 - 5, and intravenous administration of 375 mg/m² rituximab on day 6 or 7. After 3 cycles of R-MIND-E therapy, no evidence of the tumor was found including MRI (Figure 1(d)) and PET scans, therefore, he achieved a 3rd CR according to Revised Response Criteria for Malignant Lymphoma [8]. Grade 4 neutropenia, Grade 3 thrombocytopenia, and Grade 3 infection were observed according to the Common Terminology Criteria for Adverse Events version 4.0. CR has
The prognosis of systemic DLBCL has improved with the use of rituximab [1]. However, CNS recurrence occurs in 1.1% to 10.4% of patients, and the prognosis remains poor [2]. Whether the addition of rituximab decreases the risk of CNS recurrence for systemic DLBCL has not yet been proven [9-12]. The concentration of rituximab in the CSF is low even after its intravenous infusion. Some reports have suggested that a high-dose intravenous rituximab infusion or intrathecal rituximab infusion may be an effective treatment option [13], although the clinical safety of such treatments has not been yet been confirmed. In order to prevent CNS recurrence of DLBCL, intrathecal chemotherapy such as MTX and cytarabine is currently performed in many institutions, although its efficacy has been controversial [2,14-18].

Kim et al. described the treatment of 73 DLBCL patients with secondary CNS involvement in 11 institutions in Korea [14]. They reported that high-dose MTX or localized CNS-directed therapy such as whole brain irradiation was favorable for DLBCL patients with isolated secondary CNS involvement. However, they also reported that the prognosis of DLBCL patients with secondary CNS involvement was still poor, systemic recurrence occurred, and no effective treatment had been established yet. Furthermore, elderly patients who received whole brain irradiation had an increased risk of treatment-related neurotoxicity [19,20], and high-dose chemotherapy was also not feasible for these patients due to a poor performance status or disturbance of consciousness. Therefore, no effective treatment for elderly DLBCL patients with CNS recurrence had been established.

We previously reported on the use of MIND-E therapy in 8 elderly DLBCL patients with CNS recurrence. The 5 drugs used in MIND-E therapy consist of drugs that cross the blood-brain barrier or blood-retina barrier to some extent. Of the 8 patients, three achieved CR, two patients achieved a partial response, and no treatment-related mortality (TRM) was observed [3]. On the other hand, this regimen did not include rituximab; therefore, in the present case, we administered rituximab in addition to MIND-E therapy. The patient achieved a third CR after R-MIND-E therapy, and treatment-related toxicities were tolerable. Although reports concerning the treatment and response of elderly CD20+ DLBCL patients with CNS recurrence remain limited, we successfully achieved CR using R-MIND-E therapy without whole brain irradiation or high-dose chemotherapy.

To the best of our knowledge, regarding the treatment of primary CNS lymphoma, addition of rituximab for primary CNS lymphoma may be considered as standard therapy. Bimbaum et al. recently reported the benefits of rituximab in addition to MTX and IFO over MTX and IFO in 36 cases of primary CNS lymphoma in a retrospective analysis [6]. In prospective study, some investigators described promising response rate and survival in primary CNS lymphoma by multi-agent chemotherapy including rituximab as induction therapy [4,5,7]. Therefore, intravenous administration of rituximab for CNS recurrence in systemic DLBCL may be considered as a treatment option.

In conclusion, R-MIND-E therapy may be an effective and safe treatment option for elderly CD20+ DLBCL patients with CNS recurrence. However, a prospective study should be carried out to confirm the efficacy and safety of R-MIND-E therapy for elderly CD20+ DLBCL patients with CNS recurrence.

REFERENCES


Figure 2. Invasion of atypical large lymphocytes in the cerebrospinal fluid (original magnification ×1000). The size of atypical lymphocytes was double to triple as big as erythrocytes.

been maintained for 4 months.

3. Discussion

The prognosis of systemic DLBCL has improved with the use of rituximab [1]. However, CNS recurrence occurs in 1.1% to 10.4% of patients, and the prognosis remains poor [2]. Whether the addition of rituximab decreases the risk of CNS recurrence for systemic DLBCL has not yet been proven [9-12]. The concentration of rituximab in the CSF is low even after its intravenous infusion. Some reports have suggested that a high-dose intravenous rituximab infusion or intrathecal rituximab infusion may be an effective treatment option [13], although the clinical safety of such treatments has not been yet been confirmed. In order to prevent CNS recurrence of DLBCL, intrathecal chemotherapy such as MTX and cytarabine is currently performed in many institutions, although its efficacy has been controversial [2,14-18].

Kim et al. described the treatment of 73 DLBCL patients with secondary CNS involvement in 11 institutions in Korea [14]. They reported that high-dose MTX or localized CNS-directed therapy such as whole brain irradiation was favorable for DLBCL patients with isolated secondary CNS involvement. However, they also reported that the prognosis of DLBCL patients with secondary CNS involvement was still poor, systemic recurrence occurred, and no effective treatment had been established yet. Furthermore, elderly patients who received whole brain irradiation had an increased risk of treatment-related neurotoxicity [19,20], and high-dose chemotherapy was also not feasible for these patients due to a poor performance status or disturbance of consciousness. Therefore, no effective treatment for elderly DLBCL patients with CNS recurrence had been established.

We previously reported on the use of MIND-E therapy in 8 elderly DLBCL patients with CNS recurrence. The 5 drugs used in MIND-E therapy consist of drugs that cross the blood-brain barrier or blood-retina barrier to some extent. Of the 8 patients, three achieved CR, two patients achieved a partial response, and no treatment-related mortality (TRM) was observed [3]. On the other hand, this regimen did not include rituximab; therefore, in the present case, we administered rituximab in addition to MIND-E therapy. The patient achieved a third CR after R-MIND-E therapy, and treatment-related toxicities were tolerable. Although reports concerning the treatment and response of elderly CD20+ DLBCL patients with CNS recurrence remain limited, we successfully achieved CR using R-MIND-E therapy without whole brain irradiation or high-dose chemotherapy.

To the best of our knowledge, regarding the treatment of primary CNS lymphoma, addition of rituximab for primary CNS lymphoma may be considered as standard therapy. Bimbaum et al. recently reported the benefits of rituximab in addition to MTX and IFO over MTX and IFO in 36 cases of primary CNS lymphoma in a retrospective analysis [6]. In prospective study, some investigators described promising response rate and survival in primary CNS lymphoma by multi-agent chemotherapy including rituximab as induction therapy [4,5,7]. Therefore, intravenous administration of rituximab for CNS recurrence in systemic DLBCL may be considered as a treatment option.

In conclusion, R-MIND-E therapy may be an effective and safe treatment option for elderly CD20+ DLBCL patients with CNS recurrence. However, a prospective study should be carried out to confirm the efficacy and safety of R-MIND-E therapy for elderly CD20+ DLBCL patients with CNS recurrence.

REFERENCES


Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence

by Rituximab, Ranimustine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy


